The sequence contains L-alanine, L-glutamic acid, L-aspartic acid and glycine in that order. It is commonly expressed using the three-letter sequence Ala-Glu-Asp-Gly or the single-letter sequence AEDG.

The free peptide is usually represented with an unmodified amino terminus and a C-terminal carboxylic acid. Its structure can therefore be written as H-Ala-Glu-Asp-Gly-OH.

It is a short acidic peptide because both glutamic acid and aspartic acid contain additional carboxyl groups. Its behaviour in solution can depend on pH, ionic strength, counterions and formulation.

Epithalon is not a hormone replacement, a telomere transplant or a component of DNA. It is a small peptide investigated for possible effects on cellular and neuroendocrine processes.

Scientific publications most commonly use Epitalon or Epithalon. Some commercial sources use Epithalone.

FDA’s 2026 review uses the spelling Epitalon and notes that Epithalon and Ala-Glu-Asp-Gly are used as alternative terms.

The spelling alone does not reveal whether a product contains the free peptide, an acetate-associated material, an amidated derivative or another peptide.

A certificate should provide the complete sequence and chemical form rather than relying solely on a trade-style name.

Epithalon was designed from research into the amino-acid composition and proposed biological activity of Epithalamin.

Several frequently cited human “longevity” reports concern Epithalamin, sometimes in combination with thymic peptide preparations. These reports do not constitute direct human Epithalon trials.

The extract may contain multiple peptides capable of producing effects that are absent from AEDG alone. Conversely, a purified synthetic peptide may achieve a different exposure profile.

Epithalon appears in Peptides UK catalogues as a single lyophilised research peptide, an acetate-associated material or a component within products marketed around sleep and longevity.

Online descriptions frequently associate it with telomere extension, telomerase activation, younger cells, longer life, better sleep, melatonin restoration, DNA repair, immune support and cancer prevention.

These claims combine different evidence categories. Telomerase findings come largely from cultured cells, circadian findings include animal studies, and longevity findings come mainly from flies and mice.

There is no controlled human trial showing that Epithalon extends lifespan, prevents age-related disease or produces a clinically meaningful reduction in biological age.

FDA found online Epitalon products promoted for insomnia and proposed subcutaneous administration, but did not identify patient studies supporting that use or route.

FDA identified inconsistent naming and incomplete characterisation in the Epitalon compounding nominations it assessed.

Documentation sometimes listed the free-peptide formula while describing the material as Epitalon acetate. The assay basis was not always clear.

The amount of peptide cannot be determined reliably from gross powder weight where water, acetate or other counterions are present.

The pineal gland contributes to circadian timing through the synthesis and release of melatonin.

Epithalon was designed during research into the peptide composition of Epithalamin and the possibility that short amino-acid sequences could influence tissue-related gene expression.

Some authors have described AEDG as a pineal-regulating peptide. That term reflects the research hypothesis and experimental findings rather than a recognised clinical classification.

No well-established human receptor has been shown to explain how Epithalon would selectively target pineal tissue after external administration.

Laboratory findings suggesting interactions with DNA sequences, chromatin or gene expression remain mechanistic hypotheses. They do not demonstrate tissue-specific targeting in people.

Rhesus-Monkey Studies

Research in aged female rhesus monkeys reported increased evening melatonin measurements following Epithalon exposure.

One study also reported changes in the evening cortisol pattern, with the authors interpreting the findings as partial restoration of age-disrupted neuroendocrine rhythms.

A later primate publication reported changes in night-time melatonin together with selected glucose and insulin measurements.

These were small non-human-primate studies. They did not assess insomnia symptoms, sleep latency, night-time awakenings, sleep efficiency or daytime functioning in people.

Rodent Pineal Experiments

Rat experiments examined whether AEDG altered pineal melatonin secretion under young and aged conditions.

FDA noted that an in-vitro pineal-gland study did not demonstrate a straightforward direct stimulation of melatonin release.

Human Melatonin-Metabolite Study

A 2021 publication examined sublingual AEDG in women aged 40 to 50 who primarily worked night shifts.

Seventy-five women were assessed, and a subgroup with reduced urinary excretion of the melatonin metabolite 6-sulfatoxymelatonin was divided between AEDG and placebo exposure for 20 days.

The study reported changes in melatonin-metabolite excretion and selected clock-gene expression measurements.

It did not establish that participants had insomnia, and it did not demonstrate a validated improvement in sleep onset, total sleep time, sleep quality or daytime functioning.

What Are Telomeres?

Telomeres are repetitive DNA-protein structures at chromosome ends. They help protect chromosomes from being recognised as broken DNA.

Telomeres often become shorter as somatic cells divide, although length differs between tissues, cells and individuals.

Very short or dysfunctional telomeres can contribute to cellular senescence or genomic instability. Telomere length is therefore studied as one aspect of ageing biology.

What Is Telomerase?

Telomerase is a ribonucleoprotein enzyme capable of adding telomeric repeats to chromosome ends.

It is active in germ cells, selected stem cells and many cancer cells but is absent or expressed at low levels in many ordinary adult somatic cells.

The 2003 Epithalon Experiment

Researchers added Epithalon to telomerase-negative cultures of human fetal lung fibroblasts.

The publication reported expression of the catalytic telomerase component, detectable telomerase activity and increased mean and maximum telomere lengths.

The experiment used cultured cells exposed directly to the peptide under controlled laboratory conditions.

It did not administer Epithalon to living participants, measure whole-body ageing or examine lifespan.

More Recent Cell-Line Research

A 2025 study investigated Epitalon in normal epithelial cells, fibroblasts and breast-cancer-related cell lines.

The researchers reported telomere-length changes through telomerase-related or alternative-lengthening pathways depending on the cell line.

Research involving cancer cell lines reinforces the biological complexity of telomere manipulation. A response cannot be assumed beneficial merely because telomeres become longer.

Cell Concentration and Human Exposure

Laboratory studies can expose cells directly to a known concentration for a defined period.

An externally administered peptide must first survive formulation, administration, enzymatic degradation, distribution and clearance before reaching a tissue.

FDA did not identify human pharmacokinetic data for Epitalon free base or Epitalon acetate.

Drosophila Research

Experiments in fruit flies reported lifespan changes after exposure to AEDG.

Drosophila is valuable for studying genetics and ageing pathways, but insect metabolism, lifespan and peptide exposure differ substantially from human biology.

CBA Mouse Research

Studies in female CBA mice reported delayed reproductive ageing, changes in oxidative measurements and longer survival under particular experimental schedules.

These findings came from one research programme and require consideration of mouse strain, housing conditions, dose pattern and statistical methods.

Swiss-Derived SHR Mouse Study

A study involving 54 treated and 54 control female mice reported that Epitalon did not alter mean lifespan.

The researchers reported an increase in maximum lifespan and in survival among the final ten per cent of animals.

Mean lifespan and maximum lifespan are different outcomes. Reporting only the maximum result can create an exaggerated impression that the treatment extended life generally.

Senescence-Accelerated Mice

Epitalon was also examined in senescence-accelerated mouse strains alongside melatonin.

Outcomes differed between strains, reinforcing that findings were dependent on the selected genetic model.

Mouse Tumour Studies

Some mouse experiments reported lower frequencies of particular spontaneous tumours, fewer malignant tumours or altered metastasis outcomes.

A transgenic HER-2/neu mouse study reported changes in mammary-tumour development.

Another study in female C3H/He mice reported fewer malignant-tumour-bearing animals and no detected metastases in the treated group during the observation period.

The Swiss-derived SHR study did not find a reduction in total spontaneous tumour incidence, although it reported a lower leukaemia frequency.

Why the Findings Do Not Establish Cancer Prevention

Mouse strains differ greatly in their background tumour risks. Results in one strain may not reproduce in another.

Several experiments involved only female mice, fixed intermittent exposure and limited sample sizes.

Human cancer develops through diverse genetic, environmental and age-related pathways that cannot be represented by a single mouse model.

Telomerase-Related Concern

Telomerase allows cells to maintain telomeres and continue dividing.

Most human cancers use telomerase or an alternative telomere-maintenance mechanism to support continued proliferation.

FDA therefore identified a theoretical carcinogenic concern where chronic exposure activates telomerase or extends telomeres in cells capable of malignant transformation.

The available animal studies were not sufficient to resolve this concern because they did not provide a comprehensive dose-ranging, long-term carcinogenicity programme.

Female rhesus monkeys of different ages were studied to examine melatonin and cortisol secretion.

Epithalon exposure in senescent monkeys was associated with higher evening melatonin and changes in the circadian pattern of cortisol.

Related research reported changes in basal glucose and insulin measurements in older monkeys.

These studies did not establish whether the peptide improved sleep, cognition, physical function, survival or quality of life.

The number of animals was limited, and the experiments came from a small group of collaborating investigators.

Non-human-primate findings require confirmation through properly designed human studies before a treatment claim can be considered.

Night-Shift and Clock-Gene Study

The most clearly identified modern human AEDG study examined women aged 40 to 50 who primarily worked night shifts.

Participants were assessed for urinary 6-sulfatoxymelatonin, a metabolite used as an indirect measure of melatonin production.

Those with reduced measurements were divided between sublingual AEDG and placebo exposure over 20 days.

The study reported changes in the melatonin metabolite and expression of selected circadian genes.

Safety outcomes were not reported adequately, and the work was not a clinical insomnia trial.

Older Pineal-Peptide Reports

Older publications discuss Epithalamin, Epitalon or pineal peptide preparations in elderly populations.

Details concerning randomisation, blinding, chemical form, product characterisation, clinical endpoints and adverse-event monitoring are often incomplete.

Some human-longevity claims originate from studies of Epithalamin rather than Epitalon.

No Modern Longevity Trial

No large randomised trial has tested whether Epithalon reduces mortality, delays frailty, prevents age-related disease or extends healthy human lifespan.

No Human Pharmacokinetic Programme

FDA found no pharmacokinetic data defining absorption, distribution, metabolism, half-life, clearance or tissue exposure for Epitalon free base or Epitalon acetate.

Insomnia is defined by difficulty falling asleep, staying asleep or obtaining satisfactory sleep despite adequate opportunity, together with daytime consequences.

Relevant clinical trials should assess outcomes such as sleep-onset latency, total sleep time, wakefulness after sleep onset, sleep efficiency, daytime functioning and patient-reported symptoms.

Epitalon research cited in support of sleep claims generally measures melatonin, a melatonin metabolite or clock-gene expression.

FDA’s 2026 search did not identify a study in patients with insomnia and did not identify evidence for the proposed subcutaneous route.

FDA also found no nonclinical study assessing behavioural or electroencephalographic sleep endpoints following Epitalon exposure.

The mechanism through which the peptide might alter in-vivo melatonin measurements remains uncertain.

Hereditary Retinal Degeneration in Rats

Epithalon was studied in Campbell rats with inherited pigmentary retinal degeneration.

Publications reported changes in retinal structure or function and proposed that the pineal gland and retina may share aspects of developmental or transcriptional regulation.

Older Human Reports

A publication described clinical observations in patients with degenerative retinal lesions and reported favourable responses in a high proportion of cases.

The available abstract does not provide the detail expected from a modern confirmatory ophthalmology trial, including clear randomisation, masking, comparator treatment, complete adverse-event reporting and independently verified outcomes.

The evidence is not sufficient to establish Epithalon as a treatment for retinitis pigmentosa or another retinal disease.

Biological Age Is Not One Measurement

Ageing research examines genomic stability, epigenetic changes, protein homeostasis, mitochondrial function, cellular senescence, immune ageing, stem-cell function and communication between tissues.

Telomere length is one component and varies substantially between tissues and individuals.

Telomerase Is Not a Universal Rejuvenation Switch

Telomerase can support continued cell division, but the effect depends on cell type, genomic integrity and tumour-suppressor systems.

Increasing telomerase in a normal laboratory cell does not prove that every tissue becomes younger or functions better.

Animal Lifespan Does Not Equal Human Healthspan

A lifespan difference in a selected mouse strain can arise from effects on one common cause of death without improving broader health.

Human healthspan requires outcomes such as mobility, cognition, independence, cardiovascular events, cancer risk and quality of life.

No Validated Epithalon Age-Reversal Test

Commercial testing before and after Epithalon exposure cannot establish rejuvenation unless the test is validated, the change exceeds normal variation and a controlled comparator is included.

• Epithalon and Epithalamin evidence is frequently conflated.
• Several publications use different spellings and incomplete chemical descriptions.
• The free peptide and acetate-associated form are not always distinguished.
• No validated human pharmacokinetic data were identified.
• No established human half-life was identified.
• No adequate human dose-response programme exists.
• No controlled human-longevity trial was identified.
• No clinical trial established age-reversal effects.
• The main telomerase findings come from cultured cells.
• Human fetal fibroblasts do not model whole-body ageing.
• Direct cell exposure does not predict tissue exposure after administration.
• Animal-lifespan findings vary by strain and outcome.
• One mouse study found no change in mean lifespan.
• Several animal studies involved only female animals.
• Many studies used fixed intermittent exposure without full dose-ranging assessment.
• Mouse tumour findings have not been independently confirmed in humans.
• Telomerase activation creates an unresolved carcinogenicity question.
• Long-term genotoxicity information is inadequate.
• Developmental and reproductive toxicology is inadequate.
• Human immunogenicity has not been assessed adequately.
• Peptide aggregation has not been assessed in human studies.
• No patient study established insomnia effectiveness.
• Melatonin-metabolite changes are not sleep-treatment outcomes.
• Older retinal reports do not meet modern confirmatory-trial standards.
• Research-market products may not match published study material.
• Much of the work comes from overlapping authors and institutions.

What a Meaningful Epithalon Certificate of Analysis Should Include

• Complete Epitalon or Epithalon name
• Full Ala-Glu-Asp-Gly sequence
• Single-letter AEDG sequence
• Confirmation of N and C terminal groups
• Declared free-peptide or acetate form
• Observed intact molecular mass
• Tandem-MS sequence evidence
• Quantitative net peptide assay
• Chromatographic purity
• Named and unknown related-substance results
• Acetate result where applicable
• Water-content result
• Residual-solvent results
• Elemental-impurity results where appropriate
• Aggregate or higher-molecular-weight-species assessment
• Finished-product stability information
• Finished-product batch number
• Testing-laboratory identity
• Analytical methods and acceptance criteria
• A clear statement of tests not performed

Why “99% HPLC” Is Not Enough

A single chromatographic percentage does not prove that the main peak contains AEDG in the correct residue order.

It does not confirm terminal groups, acetate content, net peptide quantity, aggregation, residual solvents or finished-product stability.

For any material represented as sterile, separate validated sterility, bacterial-endotoxin and particulate testing would be required. Chemical purity alone cannot establish sterile-product quality.

No Adequate Clinical Safety Studies

FDA did not identify clinical studies designed to assess Epitalon safety in humans.

The small human clock-gene study did not provide adequate safety reporting.

No Human Pharmacokinetics

Absorption, distribution, metabolism, tissue exposure, half-life and clearance have not been established through a published clinical pharmacology programme.

Without these data, an exposure-response relationship cannot be defined.

Immunogenicity

Epithalon contains only four amino acids, but short length does not eliminate the possibility of immune responses.

Aggregates, peptide-related impurities, contaminants and formulation components may alter immune recognition.

FDA identified particular concern for proposed injectable exposure because no clinical immunogenicity or aggregation studies were available.

Telomerase and Carcinogenicity

Telomerase activation is central to the commercial anti-ageing narrative but also relevant to cancer biology.

FDA concluded that available studies were too limited to characterise genotoxic or carcinogenic potential adequately.

The agency noted that chronic telomerase activation and telomere extension could theoretically support abnormal cell survival or immortalisation.

Animal Toxicology Limitations

Some animal experiments did not report obvious toxicity or increased total tumour incidence.

These studies used restricted doses, limited exposure patterns, selected female mouse strains and incomplete toxicological endpoints.

Areas Without Adequate Human Evidence

• Long-term cardiovascular safety
• Long-term neurological safety
• Endocrine effects beyond selected hormone measurements
• Effects on glucose regulation in people
• Immune responses
• Allergic reactions
• Genotoxicity
• Carcinogenicity
• Effects in people with cancer or precancerous disease
• Reproductive and developmental toxicity
• Pregnancy safety
• Breastfeeding safety
• Paediatric exposure
• Medicine interactions
• Interaction with hormone or sleep treatments
• Repeated exposure over months or years

Product-Quality Risks

• Incorrect amino-acid sequence
• Glu and Asp residue-order errors
• Wrong terminal groups
• Incorrect free-base or acetate designation
• Incorrect peptide quantity
• Deletion-sequence impurities
• Incomplete deprotection
• Residual synthesis reagents
• Residual solvents
• Peptide aggregates
• Degradation during transport or storage
• Unverified microbiological quality
• Unverified bacterial-endotoxin control
• Certificates unrelated to the supplied batch

FDA evaluated Epitalon free base and Epitalon acetate for possible inclusion on the section 503A Bulks List.

The nominated use assessed by FDA was insomnia, with proposed subcutaneous products.

Physical and Chemical Characterisation

FDA found inconsistent naming, incomplete certificates and uncertainty about whether sources referred to the free peptide or acetate-associated material.

The agency identified concerns involving peptide-related impurities, aggregation and finished-product quality.

Historical Use

Public information suggested that Epitalon had appeared in US compounding-related contexts since at least 2018.

FDA found the evidence too limited to understand the extent and conditions of historical compounded use.

Effectiveness

FDA found no study administering Epitalon to patients with insomnia.

Available human information involved melatonin-metabolite or clock-gene measurements without corresponding clinical sleep outcomes.

No evidence supported effectiveness through the proposed subcutaneous route.

Safety

FDA found no clinical studies establishing safety, no pharmacokinetic data and no human immunogenicity or aggregation studies.

The agency also identified an unresolved carcinogenicity concern arising from reported telomerase activation and telomere extension.

FDA Staff Proposal

FDA concluded that the balance of physicochemical, historical-use, effectiveness and safety criteria weighed against adding Epitalon free base or Epitalon acetate to the 503A Bulks List.

How the MHRA Assesses Product Status

MHRA guidance states that a product may be a medicine where it is presented as preventing or treating disease.

A product may also be medicinal where it is intended to restore, correct or modify a physiological function through pharmacological, immunological or metabolic action.

Claims involving insomnia, melatonin, telomeres, age reversal, retinal degeneration, cancer prevention or hormone regulation could contribute to medicinal-product classification.

The MHRA can consider explicit statements, implied claims, ingredient properties, intended use, labels, packaging, websites, social-media posts, imagery, testimonials and instructions.

“Research Use Only” Wording

A research disclaimer does not automatically determine regulatory status.

Where the wider product presentation encourages personal administration or promises physiological effects, the MHRA may consider the complete context.

Advertising Restrictions

Regulation 279 of the Human Medicines Regulations restricts advertising medicinal products where the necessary marketing authorisation, registration or certificate is not in force.

This section provides general regulatory education and does not constitute legal advice.

Epithalon or Epitalon was not identified by name in the 2026 World Anti-Doping Agency Prohibited List reviewed for this article.

Section S0 prohibits pharmacological substances that are not addressed elsewhere in the list and have no current approval by a governmental regulatory health authority for human therapeutic use.

Epithalon has no identified current UK marketing authorisation and remains experimental.

An athlete should therefore not assume that it is permitted merely because the name does not appear expressly in the list.

Athletes should seek a formal answer from UK Anti-Doping, their international federation or another competent anti-doping organisation.

A research label or supplier assurance does not prevent an anti-doping violation.

• Does the source specify Epitalon, Epithalon or Epithalamin?
• Is the complete Ala-Glu-Asp-Gly sequence stated?
• Does the fourth residue correctly read glycine?
• Is the product free peptide or acetate?
• Is acetate being confused with N-terminal acetylation?
• Are the terminal groups identified?
• Was identity confirmed by mass spectrometry?
• Was sequence confirmed by tandem mass spectrometry?
• Was net peptide content measured?
• Were aggregates assessed?
• Does the certificate match the finished batch?
• Was the research conducted in cells, flies, mice, monkeys or humans?
• Was the human material fetal fibroblasts in a dish?
• Was telomerase measured directly?
• Was telomere length measured with a validated method?
• Was the outcome mean lifespan or maximum lifespan?
• Were both sexes studied?
• Was more than one animal strain tested?
• Was the result independently replicated?
• Was the study conducted by overlapping investigators?
• Was tumour incidence assessed comprehensively?
• Were genotoxicity and carcinogenicity assessed formally?
• Did a human study measure clinical sleep outcomes?
• Was the route the same as the commercial product?
• Were adverse events reported systematically?
• Was human pharmacokinetics measured?
• Is Epithalamin evidence being presented as Epithalon evidence?
• Is a biomarker being described as age reversal?
• Is the claimed purpose authorised in the UK?
• Is the source selling the product it describes?

The reviewers and contributors are identified to provide clear authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.

Medical Director and Clinical Reviewer

Dr Laura Geige

Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a background in dentistry, medical aesthetics and cosmetic dermatology.

Read professional profile

Medical and Nutritional Sciences Reviewer

Dr Rimas Geiga

Medical doctor with a special interest in nutritional sciences, dietology, metabolic health and evidence based preventative care.

Read professional profile

Medical and Healthcare Reviewer

Dr Snieguole Geige

Dentist and medical doctor with experience across healthcare, preventative medicine and patient centred clinical standards.

Read professional profile

Dermatology Reviewer

Dr Giedre Narkiene

Medical doctor and board certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.

Read professional profile

Medical and Gerontology Reviewer

Dr Veronika Matutyte

Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.

Read professional profile

Cosmetology and Skin Health Contributor

Livija Samušienė

Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence based aesthetic care.

Read professional profile